Sernova (XTER:PSH) Equity-to-Asset : 0.21 (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sernova Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sernova's Total Stockholders Equity for the quarter that ended in Jan. 2024 was C$3.83 Mil. Sernova's Total Assets for the quarter that ended in Jan. 2024 was C$18.57 Mil.

The historical rank and industry rank for Sernova's Equity-to-Asset or its related term are showing as below:

XTER:PSH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21 Med: 0.88 Max: 0.97
Current: 0.21

During the past 13 years, the highest Equity to Asset Ratio of Sernova was 0.97. The lowest was 0.21. And the median was 0.88.

XTER:PSH's Equity-to-Asset is ranked worse than
79.36% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs XTER:PSH: 0.21

Sernova Equity-to-Asset Historical Data

The historical data trend for Sernova's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Equity-to-Asset Chart

Sernova Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Equity-to-Asset

Get a 7-Day Free Trial

0.88

0.72

0.94

0.91

0.57

Sernova Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Equity-to-Asset	Get a 7-Day Free Trial															0.86	0.85	0.70	0.57	0.21

Competitive Comparison of Sernova's Equity-to-Asset

For the Biotechnology subindustry, Sernova's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sernova's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sernova's Equity-to-Asset falls into.

Sernova Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sernova's Equity to Asset Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Equity to Asset (A: Oct. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	12.515	/	22.107
	=

Sernova's Equity to Asset Ratio for the quarter that ended in Jan. 2024 is calculated as

Equity to Asset (Q: Jan. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	3.834	/	18.573
	=

Sernova (XTER:PSH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Sernova Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sernova's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova (XTER:PSH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (XTER:PSH) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

SEOVF:USA PSH:Germany SVA:Canada

Address

700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and or hormones for the long-term treatment of multiple serious, chronic diseases such as diabetes, hemophilia, and thyroid disease.